Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial

By Brian Orelli, PhD - Jan 27, 2020 at 6:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The results could help expand use of the drug that's currently approved to treat rheumatoid arthritis.

In a quest to expand the usage of Olumiant, Eli Lilly (LLY 0.76%) and Incyte (INCY 2.03%) have shown the drug can help patients with atopic dermatitis, commonly referred to as eczema, when used in combination with topical corticosteroids. All the patients had already failed treatment with cyclosporine, the first-line generic drug used to treat the disease.

After 16 weeks of treatment, 31.5% of patients taking the highest dose of the drug had at least a 75% or greater change from baseline in their Eczema Area and Severity Index score (EASI75), while only 17.2% of patients taking placebo met the EASI75 goal. The healthcare companies also tested two other doses of the drug, with the middle dose helping 27.6% of patients and the low dose helping 22.6% of patients, but neither dose was statistically better than placebo.

Dermatologist examining a patient's back

Image source: Getty Images.

Olumiant is approved to treat rheumatoid arthritis in more than 60 countries. The drug generated almost $300 million in sales during the first nine months of 2019. Incyte, which licensed the drug to Eli Lilly, received $57 million in royalties from Eli Lilly over that time period.

The drug works by inhibiting a protein called Janus kinase, which is involved in cell signaling in immune cells. By inhibiting JAK, Olumiant dampens the immune response in autoimmune diseases such as rheumatoid arthritis and eczema.

Eli Lilly has already applied for expanded approval to treat eczema in the EU and plans to submit applications for the disease in the U.S. and Japan this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$327.18 (0.76%) $2.47
Incyte Corporation Stock Quote
Incyte Corporation
INCY
$79.25 (2.03%) $1.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.